Issued 2026-08-13 at $13.53 · now $13.48 (2026-08-13, −0.4% since)
Based on its own history, a month from the 2026-08-13 close, EYPT has typically landed between $9.24 and $20.35 — a range of −31.7% to +50.4% from the issuance price $13.53.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
4,979 overlapping 1 month windows · 2006-09-26 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($13.53) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where EYPT has typically landed a month from the 2026-08-13 close of $13.53 — the range is history, not a prediction.
- now $13.48 (-0.4%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $13.26 (-2.0%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $10.85–$15.68
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $9.24–$20.35
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2011-10-21 | −74.0% | −74.0% | +12.3% |
| 2011-10-24 | −71.6% | −74.0% | +12.3% |
| 2011-11-03 | −71.2% | −76.5% | +0.0% |
| 3 best | |||
| 2023-11-22 | +293.7% | +0.0% | +293.7% |
| 2023-11-24 | +293.0% | −0.8% | +293.0% |
| 2023-11-27 | +283.1% | −1.0% | +292.4% |
4,979 overlapping windows · 2006-09-26 – 2026-08-13 · not cherry-picked
Pending catalysts
- October 2026 — Trial primary completion: Phase 3 primary completion: A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 (source, as of 2026-08-14)
- October 2027 — Trial primary completion: Phase 3 primary completion: COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (source, as of 2026-08-14)
- October 2027 — Trial primary completion: Phase 3 primary completion: CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.